Protocol Summaries: foretinib
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| 111645 | Phase 1 | A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects with Hepatocellular Carcinoma | Recruiting |
| MET111643 | Phase 2 | A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer | Completed |